^
    Back
    Association details:
    Biomarker:KRAS exon 2 mutation
    Cancer:Colorectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

    Excerpt:
    ...- KRAS exon 2 (codons 12/13)...
    Trial ID:
    NCT04169347
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

    Excerpt:
    ...- KRAS exon 2 (codons 12/13)...
    Trial ID:
    VOLFI
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer

    Excerpt:
    ...- KRAS exon 2 (codons 12/13)...
    Trial ID:
    NCT01668498
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

    Excerpt:
    ...Mutation in Kirsten rat sarcoma-2 virus oncogene (KRAS) status was determined by examining KRAS exons 2, 3, and 4. ...
    Trial ID:
    NCT00891930
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)

    Excerpt:
    ...- KRAS exon 2 (codons 12/13)...
    Trial ID:
    NEO-RIT
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

    Excerpt:
    These mutations were associated with inferior progression-free survival and overall survival with panitumumab–FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor.
    Secondary therapy:
    FOLFOX4
    DOI:
    10.1056/NEJMoa1305275
    Trial ID:
    PRIME